- Home
- SLN vs ELDN Comparison
SLN vs ELDN Comparison
Compare SLN & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- ELDN
- Stock Information
- Founded
- SLN 1994
- ELDN 2004
- Country
- SLN United Kingdom
- ELDN United States
- Employees
- SLN N/A
- ELDN N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- SLN Health Care
- ELDN Health Care
- Exchange
- SLN Nasdaq
- ELDN Nasdaq
- Market Cap
- SLN 165.3M
- ELDN 178.4M
- IPO Year
- SLN N/A
- ELDN N/A
- Fundamental
- Price
- SLN $3.70
- ELDN $2.89
- Analyst Decision
- SLN Buy
- ELDN Strong Buy
- Analyst Count
- SLN 5
- ELDN 1
- Target Price
- SLN $32.60
- ELDN $16.00
- AVG Volume (30 Days)
- SLN 256.3K
- ELDN 163.7K
- Earning Date
- SLN 05-08-2025
- ELDN 05-20-2025
- Dividend Yield
- SLN N/A
- ELDN N/A
- EPS Growth
- SLN N/A
- ELDN N/A
- EPS
- SLN N/A
- ELDN N/A
- Revenue
- SLN $27,701,000.00
- ELDN N/A
- Revenue This Year
- SLN N/A
- ELDN N/A
- Revenue Next Year
- SLN N/A
- ELDN N/A
- P/E Ratio
- SLN N/A
- ELDN N/A
- Revenue Growth
- SLN N/A
- ELDN N/A
- 52 Week Low
- SLN $1.97
- ELDN $2.00
- 52 Week High
- SLN $24.38
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- SLN 55.23
- ELDN 40.93
- Support Level
- SLN $3.54
- ELDN $2.85
- Resistance Level
- SLN $4.15
- ELDN $3.51
- Average True Range (ATR)
- SLN 0.33
- ELDN 0.27
- MACD
- SLN 0.06
- ELDN -0.01
- Stochastic Oscillator
- SLN 53.62
- ELDN 5.63
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.